Boston, MA 05/01/2014 (wallstreetpr) – Adamas a specialty pharmaceutical company is surging in the market after providing data on the efficacy of ADS-5102, a treatment for levodopa-induced dyskinesia. This is a serious health condition associated with the treatment of Parkinson’s. The presented data included assessment of patients receiving the treatment using Clinical Global Impression of Change metric.
Phase 2/3 Trial design
Adamas Pharmaceuticals Inc. (NASDAQ:ADMS)’s stock is surging in the market by a high of 7.05% after the trials found out that a 340mg dose of the treatment statistically resulted in significant improvement of the Parkinson’s disease versus Placebo. Senior vice president of product development Natalie McClure stated that the trial showed significant improvements while using a number of outcome measures
Mr. McClure also pointed out that Phase 2/3-EASED of the study perfectly met primary endpoint requirement making it possible for selection of a dose for future development. Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) as a result of the favorable results of the trial is advancing ADS-5102 into a phase 3 study, expected to start later in the year.
This trial was a randomized double Placebo controlled study that was conducted across the U.S. Tests were carried out on eighty three Parkinson’s patients suffering from LID a troublesome form of the illness , in which they were randomized to Placebo. The drug under testing ADS 5102 is a version of the approved drug Amantadine which is being developed for the treatment of LID a condition that occurs in patients with Parkinson disease
Phase 3 Study
Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) believes that the treatment can address a number of shortcomings of immediate-release amantadine by essentially allowing doses of amantadine to be given without any form of side effects in the future. In the EASED study, in patients taking ADS-5102, the amantadine plasma concentration achieved in the early morning through mid-day was approximately two-times that reached following administration of immediate-release amantadine, providing symptomatic relief to patients as they engaged in their daily activities
Phase 3 study will be a multi-center study Placebo-controlled and double blind with its main objective being to confirm the efficacy of 340 mg dose of ADS 5102 for the treatment of LID.
